118 related articles for article (PubMed ID: 15788007)
1. Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma.
Gianni S; Cecchetto A; Altavilla G; Ragazzi R; Bertazzo M; De Giorgio M; Baldan A; Fagiuoli S; Farinati F
J Intern Med; 2005 Apr; 257(4):367-73. PubMed ID: 15788007
[TBL] [Abstract][Full Text] [Related]
2. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.
Farinati F; Rinaldi M; Gianni S; Naccarato R
Cancer; 2000 Dec; 89(11):2266-73. PubMed ID: 11147597
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis.
Nanashima A; Omagari K; Tobinaga S; Shibata K; Sumida Y; Mine M; Morino S; Shibasaki S; Ide N; Shindou H; Nagayasu T
Eur J Surg Oncol; 2005 Oct; 31(8):882-90. PubMed ID: 15993031
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.
Huang YH; Chen CH; Chang TT; Chen SC; Wang SY; Lee HS; Lin PW; Huang GT; Sheu JC; Tsai HM; Lee PC; Chau GY; Lui WY; Lee SD; Wu JC
J Gastroenterol Hepatol; 2005 May; 20(5):765-71. PubMed ID: 15853992
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators.
Hepatology; 2000 Apr; 31(4):840-5. PubMed ID: 10733537
[TBL] [Abstract][Full Text] [Related]
8. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
9. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.
Chen CH; Hu FC; Huang GT; Lee PH; Tsang YM; Cheng AL; Chen DS; Wang JD; Sheu JC
Eur J Cancer; 2009 Jun; 45(9):1630-9. PubMed ID: 19157858
[TBL] [Abstract][Full Text] [Related]
10. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
Kudo M; Chung H; Osaki Y
J Gastroenterol; 2003; 38(3):207-15. PubMed ID: 12673442
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prognostic factors in patients with hepatocellular carcinoma.
Martins A; Cortez-Pinto H; Marques-Vidal P; Mendes N; Silva S; Fatela N; Glória H; Marinho R; Távora I; Ramalho F; de Moura MC
Liver Int; 2006 Aug; 26(6):680-7. PubMed ID: 16842324
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.
Marrero JA; Fontana RJ; Barrat A; Askari F; Conjeevaram HS; Su GL; Lok AS
Hepatology; 2005 Apr; 41(4):707-16. PubMed ID: 15795889
[TBL] [Abstract][Full Text] [Related]
14. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
[TBL] [Abstract][Full Text] [Related]
15. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program.
Ueno S; Tanabe G; Sako K; Hiwaki T; Hokotate H; Fukukura Y; Baba Y; Imamura Y; Aikou T
Hepatology; 2001 Sep; 34(3):529-34. PubMed ID: 11526539
[TBL] [Abstract][Full Text] [Related]
16. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
[TBL] [Abstract][Full Text] [Related]
17. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
[TBL] [Abstract][Full Text] [Related]
18. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis.
Schmitz KJ; Wohlschlaeger J; Lang H; Sotiropoulos GC; Kaiser GM; Schmid KW; Baba HA
J Clin Pathol; 2009 Aug; 62(8):690-3. PubMed ID: 19638539
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Cui X; Ajioka Y; Hatakeyama K
Hum Pathol; 2008 Dec; 39(12):1777-83. PubMed ID: 18701136
[TBL] [Abstract][Full Text] [Related]
20. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
